ENHERTU® - NOW AVAILABLE VIA THE CANCER DRUGS FUND FOR THE TREATMENT OF HER2 POSITIVE METASTATIC BREAST CANCER
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal & Metabolism and Respiratory & Immunology. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.
With its global headquarters in Cambridge, AstraZeneca operates in five different locations in the UK, where around 8,300 employees work in research and development, manufacturing, supply, sales and marketing. We supply 40 different medicines to the NHS. The UK is also an important location for AstraZeneca’s clinical trials; in 2018, we undertook 201 trials in the UK, involving 376 centres and over 7,000 patients.
? The black triangle means trastuzumab deruxtecan is subject to additional monitoring. This is to allow quick identification of new safety information. Patients can help with this by reporting any side effects that they experience. More information can be found online at https://www.mhra.gov.uk/yellowcard.
1 GLOBOCAN 2018. UK Cancer Fact Sheet. World Health Organization. Accessed: March 2021.
2 DeKoven M et al. J Comp Eff Res. 2012 ;1(5):453-63.
3 Sledge GW, et al. J Clin Oncol. 2014;32(19):1979-1986
4 Breast Cancer Now, 2020. Facts and Statistics 2020. Accessed: March 2021.
5 ENHERTU Summary of Product Characteristics. February 2021.
6 Modi S et al. Presented at SABCS 2020 Poster PD3-06
7 Iqbal N & Iqbal N. Mol Biol Int. 2014;852748.
8 de Melo Gagliato D, et al. Oncotarget. 2016;7(39):64431-46.
9 The National Comprehensive Cancer Network (NCCN). NCCN Guidelines Version 3.2020. Breast Cancer. June 2020.
ADC/21/0137 April 2021